Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of TherapeuticsMD Inc Are Soaring Today

By Brian Feroldi - Apr 4, 2016 at 3:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

More details on a pivotal clinical trial mixed with a bullish analyst report send shares screaming higher.

Image by PublicDomainPictures via Pixabay

What: Shares of TherapeuticsMD (TXMD -5.05%), a healthcare company primarily focused on developing products for women, were up more than 10% as of 2:35 p.m. EST Monday on two pieces of news that appear to have captured investor's attention.

So what: First, the company presented additional details from its Phase 3 Rejoice trial related to its lead compound TX-004HR over the weekend. TherapeuticsMD displayed two posters at the Endocrine Society's annual meeting in Boston that showed that patients who used TX-004HR in the trial demonstrated a statistically significant improvement in dyspareunia -- which is vaginal pain during sexual intercourse caused by vulvar and vaginal atrophy (VVA) -- and vaginal dryness when compared to patients who only used a placebo. In addition, the company also stated that the FDA gave them conditional approval to use the brand name Yuvvexy for the drug.

Secondly, the company is getting some love from the analyst community on Monday as an analyst at Goldman Sachs initiated coverage of TherapeuticsMD stock today and rated the shares a buy. The analyst based his bullishness on the data from the Rejoice trial and gave shares a $10 price target, which is quite a bit higher than the $7 and change that they are currently trading at.

The combination of positive events appears to have put traders in a good mood today, hence why shares are jumping.

Now what: Investors were likely relieved to see shares of TherapeuticsMD come back to life as they have been under pressure since the start of the year. Even after including Monday's jump they are still down nearly 30% since Jan. 1, 2016.

That shouldn't concern the company's bull too much as traders have been dumping biotech stocks in general for quite some time. For example, the iShares Nasdaq Biotechnology ETF (IBB 0.90%), a fund that holds a huge variety of stocks from the biotechnology sector, has also been a horrific performer year to date, so it's likely that TherapeuticsMD simply got caught up in the carnage.

TXMD Chart

Given the results of the Rejoice trial I think there are reasons to for investors to be optimistic about TX-004HR chances of winning regulatory approval, especially since there wasn't any clinically significant differences in the number of adverse events reported between the two groups from the trial.

From here, the company is still planning on submitting TX-004HR for FDA approval in the first half of the year, and if all goes well then the market for TX-004HR could be huge. Millions of women in the U.S. experience symptoms of VVA and yet only a tiny fraction of them are treated with a prescription therapy. That has caused some analysts to believe that TX-004HR could reach blockbuster status if it wins approval.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$115.80 (0.90%) $1.03
TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
TXMD
$2.07 (-5.05%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.